Erratum: Regulation of histone modification and chromatin structure by the p53-Padi4 pathway (Nature Communications (2012) 3 (676) doi: 10.1038/ncomms1676);Regulation of histone modification and chromatin structure by the p53-PADI4 pathway

Nature Communications

Volumn 3, Issue , 2012, Pages

  Tanikawa, Chizu ^a   Espinosa, Martha ^a,b   Suzuki, Akari ^c   Masuda, Ken ^a   Yamamoto, Kazuhiko ^c,d   Tsuchiya, Eiju ^e,f   Ueda, Koji ^c   Daigo, Yataro ^a,g   Nakamura, Yusuke ^a   Matsuda, Koichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c RIKEN   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e SAITAMA CANCER CENTER   (Japan)

^f KANAGAWA CANCER CENTER   (Japan)

^g SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CELL PROTEIN; HISTONE H4; LAMIN C; PADI4 PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; CITRULLINE; DNA; HISTONE; HYDROLASE; LAMIN A; PEPTIDYLARGININE DEIMINASE TYPE IV;

ADULT; AGED; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL DAMAGE; CELL LEVEL; CELLULAR DISTRIBUTION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN DECONDENSATION; CHROMATIN STRUCTURE; CITRULLINATION; CONTROLLED STUDY; DNA CLEAVAGE; DNA DAMAGE; DNA FRAGMENTATION; FEMALE; HISTONE MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANIMAL; BIOLOGICAL MODEL; CELL NUCLEUS; CHEMISTRY; CHROMATIN; GENE EXPRESSION REGULATION; METABOLISM; PROTEIN TERTIARY STRUCTURE; TRANSGENIC MOUSE;

MUS;

ANIMALS; APOPTOSIS; ARGININE; CELL NUCLEUS; CHROMATIN; CITRULLINE; DNA; DNA DAMAGE; GENE EXPRESSION REGULATION; HISTONES; HUMANS; HYDROLASES; LAMIN TYPE A; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; PROTEIN STRUCTURE, TERTIARY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863393260     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3638     Document Type: Erratum

References (47)

1. Levine, A. J., Hu, W. & Feng, Z. The P53 pathway: what questions remain to be explored? Cell Death and Difer. 13, 1027-1036 (2006).
2. Vogelstein, B., Lane, D. & Levine, A. J. Surfng the p53 network. Nature 408, 307-310 (2000).
3. Lane, D. P. Cancer. p53, guardian of the genome. Nature 358, 15-16 (1992).
4. Nakamura, Y. Isolation of p53-target genes and their functional analysis. Cancer Sci. 95, 7-11 (2004). (Pubitemid 38208400)
5. Oda, K. et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102, 849-862 (2000).
6. Tanaka, H. et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404, 42-49 (2000). (Pubitemid 30143125)
7. Tanikawa, C., Matsuda, K., Fukuda, S., Nakamura, Y. & Arakawa, H. p53RDL1 regulates p53-dependent apoptosis. Nat. Cell Biol. 5, 216-223 (2003). (Pubitemid 36322248)
8. Tanikawa, C. et al. XEDAR as a putative colorectal tumor suppressor that mediates p53-regulated anoikis pathway. Oncogene 28, 3081-3092 (2009).
9. Tanikawa, C., Ri, C., Kumar, V., Nakamura, Y. & Matsuda, K. Crosstalk of EDA-A2/XEDAR in the p53 signaling pathway. Mol. Cancer Res. 8, 855-863 (2010).
10. Tanikawa, C. et al. Regulation of protein citrullination through p53/PAD14 network in DNA damage response. Cancer Res. 69, 8761-8769 (2009).
11. Nakashima, K., Hagiwara, T. & Yamada, M. Nuclear localization of peptidylarginine deiminase V and histone deimination in granulocytes. J. Biol. Chem. 277, 49562-49568 (2002). (Pubitemid 36014395)
12. Neeli, I., Khan, S. N. & Radic, M. Histone deimination as a response to infammatory stimuli in neutrophils. J. Immunol. 180, 1895-1902 (2008).
13. Wang, Y. et al. Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J. Cell Biol. 184, 205-213 (2009).
14. de Seze, J. et al. IgG reactivity against citrullinated myelin basic protein in multiple sclerosis. J. Neuroimmunol. 117, 149-155 (2001). (Pubitemid 32595502)
15. Schellekens, G. A. et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 43, 155-163 (2000). (Pubitemid 30368225)
16. Goldbach-Mansky, R. et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res. 2, 236-243 (2000). (Pubitemid 32223739)
17. van Boekel, M. A., Vossenaar, E. R., van den Hoogen, F. H. & van Venrooij, W. J. Autoantibody systems in rheumatoid arthritis: specifcity, sensitivity and diagnostic value. Arthritis Res. 4, 87-93 (2002). (Pubitemid 34257342)
18. Suzuki, A. et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat. Genet. 34, 395-402 (2003). (Pubitemid 36935332)
19. Wang, Y. et al. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 306, 279-283 (2004). (Pubitemid 39336873)
20. Cuthbert, G. L. et al. Histone deimination antagonizes arginine methylation. Cell 118, 545-553 (2004). (Pubitemid 39179708)
21. Martic, G. et al. Parathymosin afects the binding of linker histone H1 to nucleosomes and remodels chromatin structure. J. Biol. Chem. 280, 16143-16150 (2005). (Pubitemid 40616739)
22. Li, P. et al. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J. Exp. Med. 207, 1853-1862 (2010).
23. Arita, K. et al. Structural basis for Ca(2+)-induced activation of human PAD4. Nat. Struct. Mol. Biol. 11, 777-783 (2004). (Pubitemid 39014504)
24. Top, B. et al. Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. Int. J. Cancer 64, 83-91 (1995).
25. Bodner, S. M. et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7, 743-749 (1992).
26. Jones, P. A. & Baylin, S. B. The epigenomics of cancer. Cell 128, 683-692 (2007). (Pubitemid 46273572)
27. Hollstein, M. et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22, 3551-3555 (1994). (Pubitemid 24299821)
28. Soussi, T. et al. Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clin. Cancer Res. 12, 62-69 (2006). (Pubitemid 43166177)
29. Beroud, C. & Soussi, T. The UMD-p53 database: new mutations and analysis tools. Hum. Mutat. 21, 176-181 (2003). (Pubitemid 36292960)
30. Jenuwein, T. & Allis, C. D. Translating the histone code. Science 293, 1074-80 (2001). (Pubitemid 32758077)
31. Celeste, A. et al. H2AX haploinsufciency modifes genomic stability and tumor susceptibility. Cell 114, 371-383 (2003). (Pubitemid 36962935)
32. Bassing, C. H. et al. Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell 114, 359-370 (2003). (Pubitemid 36962934)
33. Cheung, W. L. et al. Apoptotic phosphorylation of histone H2B is mediated by mammalian sterile twenty kinase. Cell 113, 507-517 (2003). (Pubitemid 36603322)
34. Kouzarides, T. Chromatin modifcations and their function. Cell 128, 693-705 (2007).
35. Gyorgy, B., Toth, E., Tarcsa, E., Falus, A. & Buzas, E. I. Citrullination: a posttranslational modifcation in health and disease. Int. J. Biochem. Cell Biol. 38, 1662-1677 (2006). (Pubitemid 43947646)
36. Li, P. et al. Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol. Cell. Biol. 28, 4745-4758 (2008).
37. Chang, X. et al. Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer 9, 40 (2009).
38. Brown, N. S. & Bicknell, R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its efects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 3, 323-327 (2001). (Pubitemid 32851163)
39. Toyokuni, S., Okamoto, K., Yodoi, J. & Hiai, H. Persistent oxidative stress in cancer. FEBS Lett. 358, 1-3 (1995).
40. Arita, K. et al. Structural basis for histone N-terminal recognition by human peptidylarginine deiminase 4. Proc. Natl Acad. Sci. USA 103, 5291-5296 (2006).
41. Allfrey, V. G. Structural modifcations of histones and their possible role in the regulation of ribonucleic acid synthesis. Proc. Can. Cancer Conf. 6, 313-335 (1966).
42. Denis, H. et al. Functional connection between deimination and deacetylation of histones. Mol. Cell Biol. 29, 4982-4993 (2009).
43. Li, P. et al. Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression. Oncogene 29, 3153-3162 (2010).
44. Tsukada, T. et al. Enhanced proliferative potential in culture of cells from p53-defcient mice. Oncogene 8, 3313-3322 (1993). (Pubitemid 23342629)
45. Shechter, D., Dormann, H. L., Allis, C. D. & Hake, S. B. Extraction, purifcation and analysis of histones. Nat. Protoc. 2, 1445-1457 (2007).
46. Kato, T. et al. Activation of placenta-specifc transcription factor distal-less homeobox 5 predicts clinical outcome in primary lung cancer patients. Clin. Cancer Res. 14, 2363-2370 (2008). (Pubitemid 351551069)
47. Kashiwagi, K., Nimura, K., Ura, K. & Kaneda, Y. DNA methyltransferase 3b preferentially associates with condensed chromatin. Nucleic Acids Res. 39, 874-888 (2011).